| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Risk of coronavirus disease following targeted molecular therapy in patients with inflammatory bowel disease | |
| Publish Date | 2021/09 | |
| Author | Hiroshi Nakase | Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine |
| [ Summary ] | Optimal management of patients with inflammatory bowel disease (IBD) is important during the ongoing coronavirus disease (COVID-19) pandemic. The administration of immunosuppressants in these patients remains controversial. Steroid doses adjustments are important to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent COVID-19. Studies have shown that the administration of biological agents does not affect the severity of COVID-19. Clinicians should be aware that effective management of IBD during the pandemic must necessarily focus on strict control of intestinal inflammation to reduce the risk of SARS-CoV-2 infection. | |